Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02451007 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
A Phase 2 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT02451007 is a Phase 2 study that has completed, run by PharmaMar. The registered enrollment target is 39 participants.
The verdict
NCT02451007, a Phase 2 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.
Interventions
- DRUG lurbinectedin (PM01183)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-08-12 |
| Est. Completion | 2016-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02451007
The ClinicalTrials.gov registry entry for NCT02451007 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lurbinectedin (PM01183) is the first listed.
NCT02451007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02451007 about?
NCT02451007 is a clinical study titled "Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors". Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid ...
What is the current status of trial NCT02451007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2015-08-12. Estimated completion is 2016-08-19.
What interventions are being tested in trial NCT02451007?
The interventions under investigation include: lurbinectedin (PM01183) (DRUG).
Who is sponsoring clinical trial NCT02451007?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.